Article: Investigators Present Long-Term TOBI Data at Cystic Fibrosis Conference; Lung Function Improvements Were Maintained.

MONTREAL, Oct. 16 /PRNewswire/ -- Investigators today reported 18-month clinical trial data on TOBI(R) (tobramycin solution for inhalation) at the North American Cystic Fibrosis Conference. Marketed by PathoGenesis Corp. (Nasdaq: PGNS), TOBI is approved in the U.S. for management of cystic fibrosis patients with Pseudomonas aeruginosa.

Among the important findings of the TOBI 18-month data:

-- Cystic fibrosis patients continued to maintain improved lung function

above baseline values after 18 months of the chronic intermittent TOBI

treatment regimen -- 28 days on drug, 28 days off drug. After 18

months, previously published ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!